PIKAMAB, an emerging industry leader in stratified medicine, is a biopharmaceutical company focused on developing efficacious therapeutic antibodies and theragnostic products to better treat cancers, autoimmune diseases, and inflammatory disorders.
Through our proprietary patient stratification methods, we can improve the clinical trial outcomes of several antibody candidates currently in clinical development, and help achieve superior therapeutic outcomes for several marketed antibody therapies.
News
- PIKAMAB Awarded Two Qualifying
Therapeutic Discovery Project Grants - Antitope Announces EpiScreenTM
Collaboration with PIKAMAB - PIKAMAB Secures Patent Rights Related to
IgA-mediated Autoimmune Diseases - PIKAMAB to Customize Cancer Antibody
Therapies - PIKAMAB Secures Critical Patent Rights To
Develop Theragnostic Product, Lupus
Therasight - PIKAMAB featured in Technology Review